Mink therapeutics to participate at upcoming b. riley securities virtual oncology conference

New york, jan. 12, 2022 (globe newswire) -- mink therapeutics, a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer t (inkt) cell therapies to treat cancer and other immune-mediated diseases, today announced that dr. jennifer buell, president and ceo of mink, will participate in a fireside chat at the b. riley securities virtual oncology investor conference on january 27th, 2022, at 12:00 pm et.
INKT Ratings Summary
INKT Quant Ranking